Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Altimmune Inc (NQ: ALT )

6.740 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 20,926
Open 6.740
Bid (Size) 6.780 (7)
Ask (Size) 6.800 (1)
Prev. Close 6.740
Today's Range 6.740 - 6.740
52wk Range 2.090 - 14.84
Shares Outstanding 70,902,191
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy 
Via MarketBeat
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. 
Via MarketBeat
Exposures Product Safety

Performance

YTD
-35.93%
-35.93%
1 Month
-10.01%
-10.01%
3 Month
-27.95%
-27.95%
6 Month
-35.93%
-35.93%
1 Year
+95.36%
+95.36%

More News

Read More
ALTIMMUNE, INC. (NASDAQ: ALT) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Altimmune, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Forecasting The Future: 5 Analyst Projections For Altimmune
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intel, AXT, Harbor Diversified, and Altimmune and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
Via The Motley Fool
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
Via The Motley Fool
Lowey Dannenberg Notifies Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
The 3 Smartest Biotech Stocks to Buy With $5K Right Now
Via InvestorPlace
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
From Faruqi & Faruqi LLP
Via GlobeNewswire
Why Are Altimmune Shares Trading Lower Wednesday?
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Harbor Diversified, Altimmune, Sprout Social, and Inari and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ALTIMMUNE, INC. (NASDAQ: ALT) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Altimmune, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Lowey Dannenberg Notifies Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Why Is Alimera Sciences (ALIM) Stock Up 77% Today?
Via InvestorPlace
BITF Stock Alert: Riot Platforms Is Changing Its Approach to Take Over Bitfarms
Via InvestorPlace
ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings
Via InvestorPlace
Altimmune Stock Is Rising Monday: What's Driving The Action?
Via Benzinga
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
ROSEN, A TOP RANKED LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALT
From The Rosen Law Firm PA
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Harbor Diversified, Altimmune, Sprout Social, and Inari and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Lowey Dannenberg Notifies Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
From Faruqi & Faruqi LLP
Via GlobeNewswire
TOP RANKED ROSEN LAW FIRM Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALT
From The Rosen Law Firm PA
Via GlobeNewswire
ALTIMMUNE, INC. INVESTORS: Pending Lead Plaintiff Deadline in ALT Securities Fraud Class Action; Stockholders Should Contact Robbins LLP for Information
From Robbins LLP
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.